Search

Your search keyword '"Paxlovid (Medication)"' showing total 8 results
Start Over Descriptor "Paxlovid (Medication)" Publication Year Range This year
8 results on '"Paxlovid (Medication)"'

1. Event Brief of Pfizer Inc at JPMorgan Healthcare Conference - Final

Subjects
Pfizer Inc. -- Conferences, meetings and seminars, Chairpersons -- Conferences, meetings and seminars, Business, Paxlovid (Medication)
Abstract

CORPORATE PARTICIPANTS . Albert Bourla - Pfizer Inc,Chairman of the Board, Chief Executive Officer CONFERENCE CALL PARTICIPANTS . Chris Schott - JPMorgan,Analyst OVERVIEW Company Summary FINANCIAL DATA 1. Undetermined Undetermined [...]

Published
2025

2. Pfizer Inc at JPMorgan Healthcare Conference - Final

Subjects
Pfizer Inc. -- Conferences, meetings and seminars, Chairpersons -- Conferences, meetings and seminars, Business, Paxlovid (Medication)
Abstract

Presentation CHRIS SCHOTT, ANALYST, JPMORGAN: Thank you. Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting this fireside chat with Albert Bourla, Chairman and [...]

Published
2025

3. Hong Kong: LCQ9 - COVID-19 oral drugs

Subjects
Paxlovid (Medication), Evidence-based medicine, Oral drugs, COVID-19, Oral medication
Abstract

Feb. 12 -- Hong Kong SAR Government issued the following Q&A: Following is a question by the Hon Judy Chan and a written reply by the Secretary for Health, Professor [...]

Published
2025

4. Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance

Subjects
Pfizer Inc., Paxlovid (Medication), Palbociclib, Bevacizumab, Antineoplastic agents, Antimitotic agents
Abstract

* Full-Year 2024 Revenues of $63.6 Billion, Reflecting 7% Year-over-Year Operational Growth ** Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 12% Operationally * Full-Year 2024 Reported(2) Diluted EPS of [...]

Published
2025

5. FORM 8-K: Salarius Pharmaceuticals, Inc. Files Current Report (Jan 13, 2025)

Subjects
United States. Food and Drug Administration, United States. Congress, Vertex Pharmaceuticals Inc., Employers, Securities law, Stock-exchange, News, opinion and commentary, European Union, European Union. European Commission, Paxlovid (Medication)
Abstract

Washington: Salarius Pharmaceuticals, Inc., has filed FORM 8-K (Current Report) with the U.S. Securities and Exchange Commission on Jan 13, 2025: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 [...]

Published
2025

6. LATEST COMPANY NEWS

Subjects
Pfizer Inc., GSK PLC, Roche Holding (UK) Ltd., Seagen Inc., AstraZeneca PLC, Reuters Group PLC, Eli Lilly and Co., United States. Food and Drug Administration, Association of the British Pharmaceutical Industry, European Union, European Union. European Commission, Verzenio (Medication), Mounjaro (Medication), Yervoy (Medication), Paxlovid (Medication), Opdivo (Medication), Zepbound (Medication), Jemperli (Medication), Breyanzi (Medication), BCG, Stock offerings, B cells, BCG vaccines
Abstract

Reuters - AstraZeneca overhauls management of its China division, FT reports - 18/1/2025 AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's [...]

Published
2025

7. LATEST COMPANY NEWS

Subjects
Pfizer Inc., GSK PLC, Roche Holding (UK) Ltd., Seagen Inc., Reuters Group PLC, AstraZeneca PLC, Eli Lilly and Co., United States. Food and Drug Administration, Association of the British Pharmaceutical Industry, European Union, Verzenio (Medication), Mounjaro (Medication), Yervoy (Medication), Paxlovid (Medication), Opdivo (Medication), Breyanzi (Medication), Blinatumomab, Evolocumab
Abstract

Bloomberg.com - Pfizer CEO Says Activist Wants Minimal Changes, Plays Down Fight - 14/1/2025 Pfizer Inc.'s dispute with activist firm Starboard Value LP isn't 'an aggressive situation,' Chief Executive Officer [...]

Published
2025

8. LATEST COMPANY NEWS

Subjects
Pfizer Inc., GSK PLC, Roche Holding (UK) Ltd., Seagen Inc., AstraZeneca PLC, Eli Lilly and Co., United States. Food and Drug Administration, Association of the British Pharmaceutical Industry, European Union, Nucala (Medication), Verzenio (Medication), Mounjaro (Medication), Yervoy (Medication), Paxlovid (Medication), Opdivo (Medication), Zepbound (Medication), Breyanzi (Medication), Care and treatment, Cancer treatment, Lung cancer -- Care and treatment, Blinatumomab, Nivolumab, Respiratory system agents, Anti-obesity agents, Evolocumab, Independent regulatory commissions, Drug approval, Weight loss -- Care and treatment, Semaglutide, Respiratory agents, Cancer -- Care and treatment, Weight reducing preparations
Abstract

PharmaTimes - Amgen's lung cancer treatment gets conditional approval - 6/1/2025 The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation for IMDYLLTRA (tarlatamab), a [...]

Published
2025

Catalog

Books, media, physical & digital resources
See catalog results